Breaking News Instant updates and real-time market news.

OTIC

Otonomy

$17.75

-0.1 (-0.56%)

, IONS

Ionis Pharmaceuticals

$46.27

0.52 (1.14%)

07:34
11/30/16
11/30
07:34
11/30/16
07:34

Otonomy names Kathie Bishop as Chief Scientific Officer

Otonomy (OTIC) announced the appointment of Kathie M. Bishop, Ph.D., as chief scientific officer. Dr. Bishop is a neuroscientist with more than fifteen years of pharmaceutical development experience. At Ionis Pharmaceuticals (IONS), she led translational research and development of programs in the neurology franchise including SPINRAZAa, a treatment for patients with spinal muscular atrophy that is awaiting regulatory approval. Bishop succeeds Carl LeBel, Ph.D., who had previously announced his retirement. She joins Otonomy from Tioga Pharmaceuticals where she served as chief scientific officer since 2015.

OTIC

Otonomy

$17.75

-0.1 (-0.56%)

IONS

Ionis Pharmaceuticals

$46.27

0.52 (1.14%)

  • 30

    Nov

  • 03

    Dec

  • 14

    Dec

OTIC Otonomy
$17.75

-0.1 (-0.56%)

05/10/16
PIPR
05/10/16
NO CHANGE
Target $42
PIPR
Overweight
Piper reiterates Overweight on Otonomy amid today's selloff
Piper Jaffray analyst Joshua Schimmer reiterates an Overweight rating on Otonomy amid today's post-earnings pullback. The denial of a J-code for Otoprio is not notable since it is not the appropriate code for the product, Schimmer tells investors in a research note. The analyst is confident that Otpirio will qualify for a C-code. Otiprio may have off-label use opportunities for which a J code may apply, but these are off-label, he adds. Schimmer keeps a $42 price target for the shares.
05/26/16
WBTH
05/26/16
INITIATION
Target $29
WBTH
Buy
Otonomy initiated with a Buy at WallachBeth
Target $29.
10/14/16
RHCO
10/14/16
NO CHANGE
RHCO
Otonomy named top pick at SunTrust
SunTrust analyst Edward Nash named Otonomy as his top pick. The analyst thinks that the company will benefit from strong uptake of its Otiprio drug over the next one to two quarters during peak season for ear tube surgeries. Additionally, he expects the company to report strong data for trials related to the label expansion of Otiprio and its Meniere's disease program. He keeps a $43 price target and Buy rating on the shares.
IONS Ionis Pharmaceuticals
$46.27

0.52 (1.14%)

10/10/16
WELS
10/10/16
NO CHANGE
WELS
Ionis drug likely to be approved rapidly, says Wells Fargo
After Ionis Pharmaceuticals (IONS) and partner Biogen (BIIB) reported detailed data for their RNA Therapeutic nusinersen, in patients with both symptomatic and pre-symptomatic type 1 Spinal Muscular Atrophy, as well as data for patients with type 2/3 Spinal Muscular Atrophy, or SMA, Wells Fargo says it expects the drug to be rapidly approved. The firm thinks that the FDA will approve "a broad label" covering pre-symptomatic and symptomatic type I SMA, as well as type 2/3 SMA. The firm says that the companies should have "a very large commercial opportunity," and it keeps an Outperform rating on Ionis.
11/01/16
PIPR
11/01/16
NO CHANGE
PIPR
Overweight
Piper sees thrombosis treatment from Ionis as differentiated
Piper Jaffray analyst Joshua Schimmer believes IONS-FXI is differentiated by its "potential utility in renal impairment, infrequent injections and low risk of bleeding complications." Ionis Pharmaceuticals (IONS) and its partner Bayer (BAYRY) reported positive data from a Phase 2 study of IONS-FXI, an anti-clotting antisense therapeutic which targets Factor 11 to prevent thrombosis, Schimmer tells investors in a research note. He views the recent weakness in Ionis shares as a "compelling buying opportunity" and reiterates an Overweight rating on the name.
11/07/16
PIPR
11/07/16
NO CHANGE
PIPR
Biogen, Ionis get jump start on AveXis, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says that following his upgrade this morning, Biogen (BIIB) and its partner Ionis Pharmaceuticals (IONS) announced that a Phase III study of nusinersen met its primary endpoint. The data look "very good," Schimmer tells investors in a research note. This gives Biogen and Ionis a jump start on rival gene therapy player AveXis for the Type II/III setting, Schimmer tells investors in a research note. If not for competition from AveXis, nusinersen would become a $5B-plus mega-blockbuster by addressing one of the highest unmet needs in pediatric diseases that exists today, the analyst contends. Schimmer believes, however, that AveXis is moving quickly to compete in the market. The analyst still hopes Biogen "will find a way to partner" with AveXis. He still thinks nusinersen, which is now called SPINRAZA, can achieve $1B-$2B-plus in peak annual revenue. Following this morning's upgrade, Schimmer has an Overweight rating on Biogen with a $335 price target.
11/07/16
JPMS
11/07/16
NO CHANGE
JPMS
Neutral
JPMorgan still views Ionis as fairly valued
JPMorgan analyst Jessica Fye believes the data today continue to "derisk and solidify" Spinraza's clinical profile. The analyst, however, thinks it will be difficult to lift the overhang around platelet adverse events. She continues to view Ionis Pharmaceuticals as fairly valued and keeps a Neutral rating on the shares. Ionis is up 18% to $32.10 in afternoon trading.

TODAY'S FREE FLY STORIES

C

Citi

$77.54

0.695 (0.90%)

10:38
01/16/18
01/16
10:38
01/16/18
10:38
Hot Stocks
Citi CFO says U.S. Retail Services growing slightly above outlook »

CFO John Gerspach said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

VPG

Vishay Precision

$27.30

0.55 (2.06%)

10:38
01/16/18
01/16
10:38
01/16/18
10:38
Conference/Events
Vishay Precision management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 29

    Mar

SITE

SiteOne Landscape

$71.28

-0.2 (-0.28%)

10:37
01/16/18
01/16
10:37
01/16/18
10:37
Conference/Events
SiteOne Landscape management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

IWM

iShares Trust Russell 2000 Index Fund

$159.21

1.05 (0.66%)

, RUT

Russell 2000 Index

10:36
01/16/18
01/16
10:36
01/16/18
10:36
Technical Analysis
Technical View: Russell 2000 Index crosses above 1600, new life high »

The Russell 2000 (RUT)…

IWM

iShares Trust Russell 2000 Index Fund

$159.21

1.05 (0.66%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTH

LightPath

$2.42

0.09 (3.86%)

10:36
01/16/18
01/16
10:36
01/16/18
10:36
Conference/Events
LightPath management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

LOW

Lowe's

$104.00

3.14 (3.11%)

10:35
01/16/18
01/16
10:35
01/16/18
10:35
Conference/Events
Lowe's management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

GE

General Electric

$18.17

-0.595 (-3.17%)

10:35
01/16/18
01/16
10:35
01/16/18
10:35
Periodicals
GE breakup likely, announcement may come this Spring, CNBC reports »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

C

Citi

$77.56

0.715 (0.93%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi CFO: Trading-related…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Conference/Events
UBS leisure analyst holds an analyst/industry conference call »

Leisure Analyst Farley…

ITRN

Ituran

$35.30

1.25 (3.67%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Conference/Events
Ituran management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 17

    Jan

C

Citi

$77.50

0.66 (0.86%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi sees core accrual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

AXTA

Axalta Coating

$31.99

-0.45 (-1.39%)

, UBS

UBS

$19.62

0.03 (0.15%)

10:32
01/16/18
01/16
10:32
01/16/18
10:32
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

AXTA

Axalta Coating

$31.99

-0.45 (-1.39%)

UBS

UBS

$19.62

0.03 (0.15%)

CS

Credit Suisse

$19.04

0.08 (0.42%)

NTR

Nutrien

$53.31

-0.12 (-0.22%)

CBM

Cambrex

$52.80

1.15 (2.23%)

DRNA

Dicerna

$8.42

-0.01 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

UA

Under Armour; also tag UAA

$13.13

-1.01 (-7.14%)

, UAA

Under Armour; also tag UA

$14.21

-0.91 (-6.02%)

10:32
01/16/18
01/16
10:32
01/16/18
10:32
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

UA

Under Armour; also tag UAA

$13.13

-1.01 (-7.14%)

UAA

Under Armour; also tag UA

$14.21

-0.91 (-6.02%)

VZ

Verizon

$51.84

-0.023 (-0.04%)

LMT

Lockheed Martin

$336.31

0.06 (0.02%)

COL

Rockwell Collins

$138.14

0.31 (0.22%)

SAVE

Spirit Airlines

$47.19

-1.07 (-2.22%)

FNSR

Finisar

$22.74

0.48 (2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 01

    Feb

  • 21

    Feb

  • 07

    Mar

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

, TWTR

Twitter

$24.88

-0.535 (-2.11%)

10:32
01/16/18
01/16
10:32
01/16/18
10:32
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

TWTR

Twitter

$24.88

-0.535 (-2.11%)

PG

Procter & Gamble

$90.31

0.7 (0.78%)

NOC

Northrop Grumman

$317.94

2.79 (0.89%)

CW

Curtiss-Wright

$133.63

4.893 (3.80%)

ADTN

Adtran

CIEN

Ciena

$22.69

0.75 (3.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 21

    Feb

  • 22

    Feb

  • 06

    Mar

TWTR

Twitter

$24.85

-0.565 (-2.22%)

10:32
01/16/18
01/16
10:32
01/16/18
10:32
Periodicals
Greenlight took 'small' stake in Twitter in Q4, Bloomberg reports »

Bloomberg cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

XLF

Financial Select Sector

$29.38

0.15 (0.51%)

10:30
01/16/18
01/16
10:30
01/16/18
10:30
Options
Notable spread in SPDR Financials as the sector sees strength »

Notable spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:29
01/16/18
01/16
10:29
01/16/18
10:29
Conference/Events
UBS automotive analyst holds an analyst/industry conference call »

Automotive Analyst Hummel…

10:28
01/16/18
01/16
10:28
01/16/18
10:28
General news
Tax reform optimism, Merck help push Dow up 1% to over 26,000 »

Stock futures were strong…

C

Citi

$77.60

0.76 (0.99%)

10:27
01/16/18
01/16
10:27
01/16/18
10:27
Hot Stocks
Citi CFO sees branded-cards NCL rate rising to 300bps in 2018 »

Says adjusting strategy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

CF

CF Industries

$41.63

-1.8919 (-4.35%)

10:26
01/16/18
01/16
10:26
01/16/18
10:26
Technical Analysis
Technical View: CF Industries falls sharply to session lows »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
01/16/18
01/16
10:25
01/16/18
10:25
General news
U.S. corporate bond update: moderate issuance is expected »

U.S. corporate bond…

10:25
01/16/18
01/16
10:25
01/16/18
10:25
Conference/Events
BMO Capital specialty pharma analyst holds analyst/industry conference call »

Specialty Pharmaceutical…

RIG

Transocean

$11.94

-0.263 (-2.16%)

10:25
01/16/18
01/16
10:25
01/16/18
10:25
Conference/Events
Transocean to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

UPS

UPS

$133.56

-0.53 (-0.40%)

10:23
01/16/18
01/16
10:23
01/16/18
10:23
Hot Stocks
UPS says severe weather in Louisville may cause delays »

UPS posted a service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$77.51

0.67 (0.87%)

, HLT

Hilton

$84.53

0.58 (0.69%)

10:21
01/16/18
01/16
10:21
01/16/18
10:21
Hot Stocks
Breaking Hot Stocks news story on Citi, Hilton »

Citi CFO: Hilton card…

C

Citi

$77.51

0.67 (0.87%)

HLT

Hilton

$84.53

0.58 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

  • 14

    Feb

  • 25

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.